To determine the activity and pharmacodynamics (PD) of bortezomib in platinum-sensitive epithelial ovarian or primary peritoneal cancer (EOC/PPC).
Patients and methods
Eligible women with recurrent EOC/PPC progressing between 6 and 12 months after initial chemotherapy were treated with bortezomib on days 1, 4, 8, and 11 [1.5 (cohort I) and 1.3 (cohort II) mg/m2/dose]. Patients must have had initial chemotherapy only. Response Evaluation Criteria in Solid Tumors (RECIST) was assessed by computed tomography (CT) scan every 2 cycles. 20S proteasome activity was quantified in three pre-treatment and a 1-hour post-treatment (cycle one, day 1) whole blood lysates.
Initially, 26 evaluable patients were treated at the 1.5 mg/m2/dose level. Objective response rate was 3.8% (1/26), a partial response. An additional 10 patients (38.5%) had stable disease. Given concerns that treatment discontinuations due to toxicity limited drug exposure/activity a second cohort of 29 evaluable patients was accrued at 1.3 mg/m2/dose. The 1.3 mg/m2/dose regimen is currently approved as an indication for multiple myeloma and mantle cell lymphoma. Treatment was more tolerable, although objective responses remained low at 6.9% (2/29, partial responses). Second stage accrual was not warranted at either dose. Bortezomib effectively inhibited 20S proteasome activity in whole blood lysates between 37 and 92% in 24/25 (96%) patients in cohort I, and 14–84% in 27/28 (96%) patients in cohort II who provided satisfactory pre- and post-treatment specimens for testing.
Bortezomib has minimal activity as a single-agent in the treatment of recurrent platinum-sensitive EOC/PPC. Treatment with bortezomib at 1.5 mg/m2/dose was not feasible in this patient population due to excess toxicity. Bortezomib was well tolerated at 1.3 mg/m2/dose.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gynecologic Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- New insights into proteasome function: from Archaebacteria to drug development.Chem. Biol. 1995; 2: 503-508
- The ubiquitin–proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB.Cell. 1994; 78: 773-785
- An essential role for NF-κB in preventing TNF-α-induced cell death.Science. 1996; 274: 782-784
- Suppression of TNF-α-induced apoptosis by NF-κB.Science. 1996; 274: 787-789
- TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB.Science. 1996; 274: 784-787
- Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control.Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 10057-10062
- Adhesion molecules in tumor metastasis.Semin. Cancer Biol. 1993; 4: 219-229
- The protesome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression.Immunity. 1995; 2: 493-506
- Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression.Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 3850-3855
- Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts.Cell Death Diff. 1998; 5: 1062-1075
- Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53.Oncogene. 1998; 17: 2889-2899
- Cancer statistics, 2008.CA Cancer J. Clin. 2008; 58: 71-96
- Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma.in: DeVita VT Hellman S Rosenberg RA Cancer: principles and practice of oncology, sixth ed. Lippincott Williams and Wilkins. 2001: 1597-1632
- Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.Cancer Treat. Rev. 2001; 29: 21-31
- Proteasome inhibition measurements: clinical application.Clin. Chem. 2000; 46: 673-683
- The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.Clin. Cancer Res. 2003; 9: 1136-1144
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.Blood. 2003; 101: 2377-2380
- Optimal flexible designs in phase II clinical trials.Stat. Med. 1998; 17: 2301-2312
- Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.J. Clin. Oncol. 2001; 19: 3312-3322
- PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.Mol. Cancer Ther. 2002; 1: 841-849
- Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions.J. Biol. Chem. 1998; 273: 14671-14674
- The human multi-drug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy.FASEB J. 1999; 7: 1724-1732
- The proteasome, a novel protease regulated by multiple mechanisms.J. Biol. Chem. 1999; 274: 22123-22126
- The development of proteasome inhibitors as anticancer drugs.Cancer Cell. 2004; 5: 417-421
- The proteasome: structure, function, and role in the cell.Cancer Treat. Rev. 2003; 29: 3-9
- Development of the proteasome inhibitor (Velcade ™ (Bortezomib).Cancer Invest. 2004; 22: 304-311
- Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.J. Clin. Oncol. 2005; 23: 5943-5949
- Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.Clin. Cancer Res. 2006; 12: 1270-1275
- A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.Clin. Cancer Res. 2006; 12: 1270-1275
- Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.J. Clin. Oncol. 2006; 24: 937-944
- Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.Blood. 2005; 105: 3058-3065
- Treatment of multiple myeloma.Blood. 2004; 103: 20-32
- A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.Cancer Chemother. Pharmacol. 2007; 59: 207-215
- A parallel dose-escalation study of weekly and twice weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.Clin. Cancer Res. 2007; 13: 3642-3651
- Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.Ann. Hematol. 2007; 86: 211-216
- Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in refractory multiple myeloma: combination therapy improves time to progression.J. Clin. Oncol. 2007; 25: 3892-3901
- Phase II results of study PX-171-007: A phase Ib/II study of carfilzomib (CFZ), a selective proteasomes inhibitor, in patients with selected advanced metastatic solid tumors.J. Clin. Oncol. 2009; 27 (Abstract 3515): 149s
- First-in human phase I study of the novel structure proteasomes inhibitor NPI-0052.J. Clin. Oncol. 2009; 27 (Abstract 3516): 150s
Received: May 19, 2009
© 2009 Elsevier Inc. Published by Elsevier Inc. All rights reserved.